patients with type 2 diabetes
Conditions
Interventions
dapagliflozin
Sponsors
Diamond study group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet all of the following requirements. 1. Patients with type 2 diabetes and HbA1c more than 6.5% 2. Estimated GFR more than 45 mL/min 1.73m2 3. Patients who provide their consent form
Exclusion criteria
Exclusion criteria: Patients who meet one of the following criteria are ecluded. 1. Patients treated with insulin 2. Patients with unstable angina 3. Patients with severe liver dysfunction (AST >= 100IU/L or ALT >= 100IU/L) 4. Patients with severe renal dysfunction (eGFR < 45 mL/min/1.73m2) 5. Known hypersensitivity to dapagliflozin 6. Patients who are pregnant, possibly pregnant, or nursing 7. A history of traetment with SGLT2 inhibitors including dapagliflozin 8. Patients disqualified by doctor for any reason
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes from baseline to day 5-9 in GFR evaluated by inulin clearance | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes from baseline to month 6-12 in hepatic fat amount | — |
Countries
Japan
Contacts
Public ContactKatsuhito Mori
Osaka City Graduate School of Medicine Department of Metabolism, Endocrinology and Molecular Medicine
Outcome results
None listed